about
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signallingOncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingDirect association of Sprouty-related protein with an EVH1 domain (SPRED) 1 or SPRED2 with DYRK1A modifies substrate/kinase interactionsMLK3 is required for mitogen activation of B-Raf, ERK and cell proliferationWnt4 inhibits cell motility induced by oncogenic RasSynthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsNovel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch IIPar-4 inhibits Akt and suppresses Ras-induced lung tumorigenesisA functional family-wide screening of SP/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growthUSP17 regulates Ras activation and cell proliferation by blocking RCE1 activityThe RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsA landscape of driver mutations in melanomaRetroviral oncogenes: a historical primerKirsten Ras* oncogene: Significance of its discovery in human cancer researchGenomic alterations in pancreatic cancer and their relevance to therapySkin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.Human β-cell proliferation and intracellular signaling: part 3Mutationally activated Rho GTPases in cancerBeyond BRAF: where next for melanoma therapy?K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesisThe coordination of cell growth during fission yeast mating requires Ras1-GTP hydrolysisAblation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellumTargeting the RAS oncogene.Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careMechanisms of resistance to anti-EGFR therapy in colorectal cancerOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerJMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entitiesA germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinomaSignalling scaffolds and local organization of cellular behaviourRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancerExpression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cellsThe C-terminus of H-Ras as a target for the covalent binding of reactive compounds modulating Ras-dependent pathwaysDLC1: a significant GAP in the cancer genomeThe N-terminal domain of ERK1 accounts for the functional differences with ERK2A gain-of-function germline mutation in Drosophila ras1 affects apoptosis and cell fate during developmentBAY61-3606 affects the viability of colon cancer cells in a genotype-directed mannerKSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signalsThe intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
P2860
Q24293500-A5FACB7C-B4F2-4C2D-87A1-AD872C8C6066Q24296451-C05346EB-5546-4373-83A4-EA9AC45B1624Q24297221-4BDBF3E1-1DCC-4EB5-9B93-4FC27B6D7A87Q24299564-F78B66F8-E2FF-4E4A-A55D-0AED8D63836CQ24299974-4353749C-6A0E-404B-9DBC-6FDCD46C0F26Q24306326-712EF145-D861-4BB3-A26A-E584B9664D78Q24309371-0162742C-6ADF-439E-82B5-E501CE16ADD4Q24316409-8DA18B97-7885-4263-9D1B-FA90AA50EDA4Q24318407-3444304E-0756-4F20-89D6-2ECBACE80D3FQ24328791-47CEB3DF-C0C8-4006-94C8-A208E1CA1E05Q24519206-90F858E7-8A24-4741-A3C0-146D9DB6CDE0Q24603357-4860DD40-B8DD-42CE-928A-EE24495F8232Q24611142-B5A36B97-8B26-45AD-85AD-BBE7B36F78F1Q26751212-37159933-6EE5-4FC8-A3A0-AE21255D3E45Q26781443-297C5675-B19A-4DE8-B035-682286310120Q26783914-76F22D45-8983-4D05-AEF9-2B3510C25E73Q26821954-508FF83C-9666-45A8-BE36-241622696BA8Q27000042-1D9D2229-5ACA-45A5-854F-834C2AC73F30Q27006853-9667E060-B3F5-4FBF-9B59-22D76A3FC3AAQ27300812-F0AC4794-7FAA-4DA3-A0B2-8DA60503306CQ27303856-8C9E1A4A-9474-4984-B4A2-2EEB31EF3FEFQ27335279-5E65A71B-EA6E-4D27-87A4-4432FC27B635Q27687198-5C3DE89C-312F-4A18-A741-06C21FEF760AQ27852136-1761EB6E-BC93-446A-90B5-3DF8590A546FQ28066460-BC70919B-742C-45B6-974F-B0460ADEE30DQ28074073-642C11E4-E180-49F7-B58B-0D036B056E3EQ28077545-3A502AB1-8916-485F-A85F-F84741D999DDQ28082598-E7B844A0-5912-4760-8D97-65542A7A89EFQ28118410-E8021441-6B1C-42B8-AA66-DCAF539B66B5Q28259061-386BA47C-5DD7-4C1A-B61D-AC69C10004FEQ28260541-8F2AA178-BF48-45FE-AEA9-1181109C20B8Q28283044-3B90F6B6-B76A-46EF-8D32-36B70EF6498DQ28306273-CCFEA61B-0C5B-4EB3-8D90-32E8DE20D5BAQ28385612-632BAEB8-A186-488C-BD9B-9767030D724AQ28390592-A2C2B5D0-F9F1-4859-9C90-5D058572CA0EQ28474123-7BE4FAE1-83DF-4141-AA12-9CB69AEC2457Q28476541-D539F8B5-087B-4878-B708-0F6E651DE7BFQ28481390-D862BBA2-2DA4-4469-A00B-0A6010138D8AQ28507994-AE920790-5645-48F0-B250-E835951A4328Q28512744-5058C1AD-BC23-4FC0-8FCE-F6257734DAB0
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
RAS oncogenes: the first 30 years.
@en
RAS oncogenes: the first 30 years.
@nl
type
label
RAS oncogenes: the first 30 years.
@en
RAS oncogenes: the first 30 years.
@nl
prefLabel
RAS oncogenes: the first 30 years.
@en
RAS oncogenes: the first 30 years.
@nl
P356
P1476
RAS oncogenes: the first 30 years.
@en
P2093
Mariano Barbacid
P2888
P304
P356
10.1038/NRC1097
P407
P577
2003-06-01T00:00:00Z
P5875
P6179
1044819609